Avax Initiates Lung Cancer Vaccine Trial
Posted on: Thursday, 19 January 2006, 15:00 CST
Avax Technologies is commencing enrollment in its phase I/II study in patients with non-small cell lung cancer.
The vaccine is composed of tumor cells obtained from each patient's tumor that are modified with dinitrophenyl. Endpoints of the study include safety and a measure of each patient's immune response to their cancer after vaccination using a delayed-type hypersensitivity test.
"Based upon previous observations of regression of melanoma lung metastases after administration of M-Vax, our AC Vaccine Therapeutic for the treatment of melanoma plus initial results obtained in our animal model, we feel there is a strong rationale for testing the vaccine in lung cancer," Dr David Berd, chief medical officer of Avax.
The study will include patients whose lung cancers are completely resectable. They will be assigned to one of three vaccine doses, and the dose is measured by the number of cancer cells. Each dosage arm will include a maximum of 14 patients.
The study subjects will receive vaccine treatment immediately after surgery and prior to any other adjuvant treatment. Based upon anticipated enrollment the company expects to obtain initial immunological data from the study in the second quarter of 2006.
Source: Datamonitor
Related Articles
- Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
- New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Nereus Initiates Phase Ib Study of Lung Cancer Drug
- Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
- Natural Products Association Challenges New Study on Lung Cancer and Vitamin Use
- Pill Gives New Hope in Lung Cancer Fight Patients Get More Time With Loved Ones at Home
- STELLAR 3 Pivotal Trial Shows XYOTAX(TM) Reduces Side Effects of Paclitaxel With Equivalent Efficacy in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients
- Study of Lung Cancer Drug Iressa Under Way
- CT Scans Studied in Lung Cancer Screening
 |
 |
User Comments (0)
RSS Feeds